<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372190</url>
  </required_header>
  <id_info>
    <org_study_id>P0609</org_study_id>
    <nct_id>NCT00372190</nct_id>
  </id_info>
  <brief_title>Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.</brief_title>
  <official_title>A Prospective and Comparative Study of the Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pelvic organ prolapse is a common problem. A lot of women have surgery for prolapse. The
      recurrence rate op pelvic organ prolapse after surgical treatment is high. Placement of a
      mesh aims at reducing the recurrence rate, but mesh implants can cause complications.

      This study is designed to determine the effectiveness of one type of mesh (tensionfree
      vaginal mesh; Prolift), compared with the standard prolapse surgery. A secondary objective is
      to track the complications of both procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with recurrent prolapse after surgery can participate in this study. A total of 194
      women will be included. At random 97 patients undergo a standard prolapse operation and 97
      patients undergo an operation with the mesh. Evaluation will take place during surgery, at
      the postoperative visit after six weeks, and after six months and twelve months. Quality of
      life, degree of vaginal prolapse, subjective effectiveness, safety and incidence of
      complications will be evaluated.

      An amendment to the original study has been approved by the Ethical Committee to examine long
      term outcome of this RCT at 7 years. This study was completed in december 2015.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolapse by &quot;Pelvic Organ Prolapse Quantification System&quot; (POP-Q), at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with anatomic failures defined as &quot;Pelvic Organ Prolapse&quot; (POP) stage II or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mesh Exposure at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>cumulative number of patients with mesh exposure at 12 months (if diagnosed at 6 weeks or 6 months and treated, the exposure is calculated at 12 months, even if the exposure was not there anymore)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;Patient Global Impression of Improvement&quot; (PGI-I) at 12 Months</measure>
    <time_frame>at 12 months</time_frame>
    <description>Number of participants with much to very much improvement compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulge Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Bulge symptoms defined as Prolapse domain score of the &quot;Urogenital Distress Inventory&quot; (UDI) at 12 months.
Scores range from 0 (least/no bother) to 100 (maximum bother)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Mesh surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trocar guided tension free vaginal mesh insertion by Prolift mesh kit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional vaginal surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classical vaginal prolapse surgery (fascia plication)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tensionfree vaginal mesh kit (Prolift)</intervention_name>
    <description>Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
    <arm_group_label>Mesh surgery</arm_group_label>
    <other_name>Prolift mesh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>classic vaginal prolapse surgery (fascia plication)</intervention_name>
    <description>classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
    <arm_group_label>Conventional vaginal surgery</arm_group_label>
    <other_name>Conventional</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent anterior and/or posterior prolapse POP-Q stage 2 or more

          -  patient has agreed to undergo implantation of TVM (prolift) or fascial plication

          -  patient is willing to return for follow-up evaluation at 6 weeks, 6 months and 12
             months

          -  patient is willing to complete quality of life questionnaires at 6 and 12 months

        Exclusion Criteria:

          -  patient is or wants to become pregnant

          -  patient has had previous synthetic mesh procedure (a previous mid-urethral sling
             procedure is NOT an exclusion criterion)

          -  patient has current urinary tract or vaginal infections

          -  patient has a blood coagulation disorder

          -  patient has a compromised immune system or any other condition that would compromise
             healing

          -  patient has renal insufficiency and/or upper urinary tract obstruction

          -  patient is unwilling or unable to return for evaluation

          -  patient has had previous irradiation

          -  patient has any malignancy

          -  patient has large ovarian cysts of large myoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariella ij Withagen, Drs.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gelre ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slysis Zorggroep, location Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Refaja</name>
      <address>
        <city>Stadskanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twee Steden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Withagen MI, Milani AL, den Boon J, Vervest HA, Vierhout ME. Trocar-guided mesh compared with conventional vaginal repair in recurrent prolapse: a randomized controlled trial. Obstet Gynecol. 2011 Feb;117(2 Pt 1):242-50. doi: 10.1097/AOG.0b013e318203e6a5.</citation>
    <PMID>21252735</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <results_first_submitted>September 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Mariella Withagen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pelvic organ prolapse</keyword>
  <keyword>recurrence</keyword>
  <keyword>mesh</keyword>
  <keyword>complications</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesh</title>
          <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit.
95 randomized for mesh, 2 refused surgery; 93 underwent mesh insertion</description>
        </group>
        <group group_id="P2">
          <title>Conventional</title>
          <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
99 randomized to conventional surgery, 1 refused surgery for comorbidity, 1 died prior to surgery; 97 underwent conventional surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93">95 were allocated to mesh group, however 2 never underwent any surgery</participants>
                <participants group_id="P2" count="97">99 were allocated to conventional arm, however 2 never underwent any surgery</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesh</title>
          <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
        </group>
        <group group_id="B2">
          <title>Conventional</title>
          <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>age at randomization</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10.5"/>
                    <measurement group_id="B2" value="64" spread="10.2"/>
                    <measurement group_id="B3" value="64" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prolapse by &quot;Pelvic Organ Prolapse Quantification System&quot; (POP-Q), at 12 Months</title>
        <description>Number of participants with anatomic failures defined as &quot;Pelvic Organ Prolapse&quot; (POP) stage II or higher</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesh</title>
            <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit.
95 randomized for mesh, 2 refused surgery; 93 underwent mesh insertion</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
99 randomized to conventional surgery, 1 refused surgery for comorbidity, 1 died prior to surgery; 97 underwent conventional surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Prolapse by &quot;Pelvic Organ Prolapse Quantification System&quot; (POP-Q), at 12 Months</title>
          <description>Number of participants with anatomic failures defined as &quot;Pelvic Organ Prolapse&quot; (POP) stage II or higher</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anatomic failures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anatomic success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no anatomic evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mesh Exposure at 12 Months</title>
        <description>cumulative number of patients with mesh exposure at 12 months (if diagnosed at 6 weeks or 6 months and treated, the exposure is calculated at 12 months, even if the exposure was not there anymore)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesh</title>
            <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
          </group>
        </group_list>
        <measure>
          <title>Mesh Exposure at 12 Months</title>
          <description>cumulative number of patients with mesh exposure at 12 months (if diagnosed at 6 weeks or 6 months and treated, the exposure is calculated at 12 months, even if the exposure was not there anymore)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>&quot;Patient Global Impression of Improvement&quot; (PGI-I) at 12 Months</title>
        <description>Number of participants with much to very much improvement compared to baseline</description>
        <time_frame>at 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesh</title>
            <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Patient Global Impression of Improvement&quot; (PGI-I) at 12 Months</title>
          <description>Number of participants with much to very much improvement compared to baseline</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bulge Symptoms</title>
        <description>Bulge symptoms defined as Prolapse domain score of the &quot;Urogenital Distress Inventory&quot; (UDI) at 12 months.
Scores range from 0 (least/no bother) to 100 (maximum bother)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesh</title>
            <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
          </group>
          <group group_id="O2">
            <title>Conventional</title>
            <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
          </group>
        </group_list>
        <measure>
          <title>Bulge Symptoms</title>
          <description>Bulge symptoms defined as Prolapse domain score of the &quot;Urogenital Distress Inventory&quot; (UDI) at 12 months.
Scores range from 0 (least/no bother) to 100 (maximum bother)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="17"/>
                    <measurement group_id="O2" value="5" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mesh</title>
          <description>Insertion of Tensionfree vaginal mesh (Prolift)
Tensionfree vaginal mesh kit (Prolift): Insertion of a tension free vaginal mesh using a Prolift mesh kit</description>
        </group>
        <group group_id="E2">
          <title>Conventional</title>
          <description>Classical vaginal prolapse surgery (fascia plication)
classic vaginal prolapse surgery (fascia plication): classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Repeat surgery for postoperative hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>de novo SUI</sub_title>
                <description>you can only develop de novo SUI, if you had no SUI before, therefore the number is different from the total number of women at risk</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>de novo dyspareunia</sub_title>
                <description>you can only develop de novo dyspareunia, if you had no dyspareunia before. therefore the number of women at risk is lower than in total</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mesh exposure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. M.I.J.Withagen</name_or_title>
      <organization>Radboud University Medical Center</organization>
      <phone>+31 6 51262468</phone>
      <email>M.I.J.Withagen@umcutrecht.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

